Skip to main content
RLAY logo

RLAY · Relay Therapeutics, Inc. · Documents

Track RLAY — free
$16.12 +0.21 (+1.32%) At close · Nov 20
Market Cap
$3.56B
Shares
220.96M
Volume · Nov 20 3.98M Avg daily vol (3M) 2.93M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $15.36M up 53.4% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Net loss $81.75M 10-Q filed Nov 4, 2026 Latest results Lirafugratinib wins FDA approval with $848.6 million cash 8-K filed Nov 4, 2026
2026
Nov 18
Investor event
Zovega Enters Three Pivotal Trials; Cash Runway Into 2029

Relay's CEO said its PI3K alpha mutant-selective asset, Zovega, is moving into three pivotal trials, including a second-line breast cancer trial expected to be fully enrolled by mid-2027. The company reported $849 million of cash, which should last well into 2029. Relay plans an update on vascular anomalies data at ASH in December.

4 source passages
We have Zovega, which is our PI3K alpha mutant selective asset, now moving forward, hopefully soon, in three pivotal trials. We announced a couple of weeks ago that we'll have this trial fully enrolled by the middle of 2027. and we have $849 million of cash. It should take us well into 2029. we will show data at ASH in December that will update the data that we We showed back in May Open the document at this passage
Nov 10
Investor event
ASH data on all 32 patients follows 60% response rate

Relay will present ASH data on all 32 patients from its dose randomization portion, after showing a 60% volumetric response rate across three doses at ISFA in May. Management models five and a half months of median PFS for CAPI. Pfizer supplies termociclib under a clinical trial supply agreement for a frontline trial due to start early next year.

4 source passages
At ASH, what we'll show is those 32 patients again, and we'll show now efficacy and safety data on all 32 patients. back in ISFA, we showed across those three doses a 60% volumetric response rate. there's enough data out there now that makes us confident to model five and a half months. We have a clinical trial supply agreement in place with Pfizer where they supply a termociclib, their selective CDK4 molecule, for our frontline trial that we're on track to start early next year. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash runway extends into 2029

Relay Therapeutics said cash, cash equivalents and investments of $848.6 million as of September 30, 2026 should fund operations into 2029. Nine-month net loss was $238.7 million, while zovegalisib received FDA Breakthrough Therapy designation with fulvestrant.

Net loss $81.75M Diluted EPS -$0.37
Read from the MD&A section
3 source passages
We believe our cash, cash equivalents, and investments of $848.6 million as of September 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements into 2029. Our net losses were $238.7 million and $221.6 million for the nine months ended September 30, 2026 and 2025, respectively. In February 2026, we announced that the FDA granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for the treatment of adults with PIK3CA mutant HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor. Open the document at this passage
Nov 4
Current report 8-K
Lirafugratinib wins FDA approval with $848.6 million cash

Relay Therapeutics reported full FDA approval of LYRFIGTU™ (lirafugratinib) for cholangiocarcinoma with FGFR2 fusion or other rearrangement, $848.6 million in cash and investments, and zovegalisib trial enrollment expected to complete in mid-2027.

Financial results
3 source passages
The FDA granted full approval for LYRFIGTU™ (lirafugratinib) as a treatment option for patients with cholangiocarcinoma (CCA) with FGFR2 fusion or other rearrangement. As of September 30, 2026, cash, cash equivalents and investments totaled $848.6 million, as compared to $910.9 million as of June 30, 2026. Complete enrollment of Phase 3 ReDiscover-2 trial in 2L breast cancer estimated in mid-2027 Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $350K ▼ 48.3% Net loss $83.71M Diluted EPS -$0.41
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $3M ▼ 60.9% Net loss $73.29M Diluted EPS -$0.41
Apr 28
Proxy statement DEF 14A Meeting Jun 9, 2026
Proxy statement AI summary on its way
Apr 16
Proxy statement PRE 14A Meeting Jun 9, 2026
Proxy statement AI summary on its way
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $15.36M ▲ 53.4% Net loss $276.48M Diluted EPS -$1.61
2025
Feb 26
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $10.01M ▼ 60.8% Net loss $337.71M Diluted EPS -$2.36
2024
Showing 1–50 of 131 documents
Key facts CIK 1812364 CUSIP 75943R102 13F (30d) 276 filings 247 filers Visit website Investor relations